Merck Sharp & Dohme slams Wyeth vaccine patent claims as ‘hearsay and speculation’

Allens 2019-02-06 8:17 pm By Miklos Bolza | Sydney

Please login to bookmark

Claims by Wyeth that its patented Prevnar 13 pneumococcal vaccine was inventive because other pharmaceutical giants had failed in developing similar vaccines are based on “hearsay and speculation,” Merck Sharp & Dohme told the court during closing submissions in the high-stakes trial over the world’s best-selling vaccine.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au